Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Iyer, Priyanka C., Cabanillas, Maria E., Waguespack, Steven G., Hu, Mimi I., Thosani, Sonali, Lavis, Victor R., Busaidy, Naifa L., Subudhi, Sumit K. +2 more·2018·Thyroid
DOI 10.1089/thy.2018.0116

Cited by (239)

Items 101–200 of 239

  1. Immunological Mechanisms of Autoimmune Thyroid Diseases: A Shift in The Traditional TH1/TH2 Paradigm
    Tatjana Zaķe, Sandra Skuja, Aivars Lejnieks, Valērija Groma, Ilze Konrāde · 2019 · Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences
  2. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies
    Alexandra Frelau, Eva Jali, Boris Campillo‐Gimenez, Marc Pracht, Marc Porneuf, Monica Dinulescu, Julien Edeline, Lise Boussemart, Thierry Lesimple · 2021 · Melanoma Research
  3. Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy
    Jun Ni, Li Zhang, Xiaotong Zhang · 2020 · European Journal of Cancer
  4. Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer
    Andrea Palermo, Andrea Napolitano, Daria Maggi, Anda Mihaela Naciu, Gaia Tabacco, Silvia Manfrini, Anna Crescenzi, Chiara Taffon, Francesco Pantano, Bruno Vincenzi et al. · 2020 · European Thyroid Journal
  5. Advancements in theranostic applications: exploring the role of fibroblast activation protein inhibition tracers in enhancing thyroid health assessment
    Yuhua Wang, Ye Liu, Huixia Geng, Wanchun Zhang · 2023 · EJNMMI Research
  6. Nivolumab Associated Endocrine Abnormalities: Challenging Cases from a Reference Clinic
    Mehmet Çağrı Ünal · 2022 · Acta Endocrinologica (Bucharest)
  7. Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
    Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong et al. · 2022 · Endocrinology and Metabolism
  8. Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis
    Jun Zhao, Yujie Feng, Guangwei Liu · 2024 · Heliyon
  9. Post-immunotherapy imaging in lung cancer
    Girish S. Shroff, Chad D. Strange, Mehmet Altan, B.W. Carter, Jitesh Ahuja, Myrna C. B. Godoy, Mylene T. Truong, Ioannis Vlahos · 2021 · Clinical Radiology
  10. Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
    Yanling Wang, Xiaoxuan Yang, Jia Ma, Shenglan Chen, Ping Gong, Ping Dai · 2024 · Heliyon
  11. Real-World Outcomes of Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma: A National Population-Based Cohort Study
    Chin Hang Yiu, Adrian Lee, Christine Y. Lu · 2025 · Targeted Oncology
  12. Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia
    Chin Hang Yiu, Stephen John Clarke, Christine Y. Lu · 2026 · Clinical Pharmacology & Therapeutics
  13. Multi‐organs perioperative immune‐related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC
    Yuan Xu, Xiaohong Lyu, Yingzhi Qin, Dongjie Ma, Mengzhao Wang, Juhong Shi, Yun Long, Bo Tang, Hongsheng Liu · 2022 · Thoracic Cancer
  14. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice
    Ioannis Parthymos, George L. Liamis, Evangelia C. Dounousi, George E. Pentheroudakis, Davide Mauri, George Zarkavelis, Matilda Florentin · 2020 · Critical Reviews in Oncology/Hematology
  15. Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study
    Haoting Zhang, Jing Zheng, Chenyi Ren, Chenlin Ye, Xiaoyu O. Wu, Xiaodong Lv, Yuping Li, Jianya Zhou, Jianying Zhou · 2025 · BMC Pulmonary Medicine
  16. Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy
    Maria A. Velez, Elliot Kang, Chester Andrew Thompson, Jackson P Lind-Lebuffe, Collin Shen, Seung Jun Park, Andy Han, Arjan Gower, Daniel Li, Philippe Rochigneux et al. · 2025 · JCO Oncology Practice
  17. Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors
    Fumika Kamitani, Yuichi Nishioka, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi · 2025 · The Journal of Clinical Endocrinology & Metabolism
  18. Environmental factors and anatomic pathology of the thyroid gland: review of literature
    Manuel Lora Gonzalez, Rebecca D. Chernock, Mena Mansour · 2020 · Diagnostic histopathology
  19. Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience
    Poupak Fallahi, Armando Patrizio, Alessandro Antonelli, Silvia Martina Ferrari · 2022 · Current Pharmaceutical Design
  20. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
    Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada et al. · 2023 · Endocrine Journal
  21. Characterizing Thyroid Hormone Replacement, Baseline Thyrotropin, and Survival in Immune Checkpoint Inhibitor–Associated Thyroid Dysfunction
    Duaa Abdallah, Jake N Johnson, Fang Qiu, Whitney Sears Goldner, Apar Kishor Ganti, Anupam Kotwal · 2025 · Thyroid
  22. The Year in Medical Thyroidology Review: Current Challenges and Future Directions
    Naifa Lamki Busaidy · 2019 · Thyroid
  23. Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma
    Ying Chen, Lei Zhuang, Danhong Zhang, Xianghui Du, Liming Sheng · 2022 · Journal of Immunology Research
  24. Thyroid Dysfunction from Treatments for Solid Organ Cancers
    Anupam Kotwal, Donald S.A. McLeod · 2022 · Endocrinology and Metabolism Clinics of North America
  25. Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review
    Remya Rajan, Devika Nandakumar · 2025 · Indian Journal of Endocrinology and Metabolism
  26. Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
    Sara Salehi Hammerstad, Hanna J. Lee, Yaron Tomer, Mihaela Stefan–Lifshitz · 2025 · Journal of Endocrinological Investigation
  27. Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [18F]FDG PET/CT
    Clemens P. Spielvogel, Aleksa Lazarevic, Lucia Zisser, David Haberl, Christophoros Eseroglou, Lucian Beer, Marcus Hacker, Raffaella Calabretta · 2025 · European Journal of Nuclear Medicine and Molecular Imaging
  28. Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study
    Yu Bai, Yue Yin, Yuanyuan Jiao, Yanhua Zhang, Hong Liu · 2025 · Endocrine
  29. Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study
    Chin Hang Yiu, Stephen John Clarke, Christine Y. Lu · 2026 · Lung Cancer
  30. Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes
    Amy Armstrong, Yuting Tang, Neelam Z. Mukherjee, Nu Zhang, Gang Huang · 2024 · Frontiers in Immunology
  31. Thyroid disorders associated with immune control point inhibitors
    Enzamaría Fidilio, Elena Navarro-González, Ana R. Romero-Lluch, Pedro Iglesias, Juan José Díez Gómez, Emma Anda Apiñániz, Estefanía Santos Mazo, Carles Zafón · 2021 · Endocrinología Diabetes y Nutrición (English ed )
  32. Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications
    Hyesun Park, Akinori Hata, Hiroto Hatabu, Biagio Ricciuti, Mark Magdi Awad, Mizuki Nishino · 2023 · Cancers
  33. Replacement Dose for Overt Hypothyroidism Induced by Programmed Cell Death Protein 1 Antibodies May Be Higher than Recommended
    Qian Zhang, Yao Zhang, Huijuan Zhu, Kuanzhi Liu, Pingping Lou, Peixuan Kong, Lei Su, Shuchang Wang · 2023 · Endocrine Metabolic & Immune Disorders - Drug Targets
  34. Profound postinduction hypotension precipitated by immune checkpoint inhibitors: a case report
    Lu Che, Afang Zhu, Wen Chen, Chunhua Yu · 2024 · Journal of Medical Case Reports
  35. Endocrine immune-related adverse events: a double-edged sword?
    Michelle Rengarajan, Justin F. Gainor · 2021 · Translational Lung Cancer Research
  36. T3 and T4 autoantibodies: emerging biomarkers for evaluating thyroid disorders
    Jiameng Liu, Chaoming Mao, Xueqian Mao, Xi Wang, Tingting Zheng, Liyang Dong, Yufei Mao · 2025 · Frontiers in Endocrinology
  37. The Role of FAPI PET/CT in the Assessment of Inflammatory Diseases
    Elnaz Jenabi, Masatoshi Hotta, Armin Atzinger, Elizabeth Volkmann, Theresa Jung, Matthieu Bailly, Christian Pirich, Jérémie Calais, Torsten Kuwert, Mohsen Beheshti · 2026 · Seminars in Nuclear Medicine
  38. Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
    Xiaowan Xie, Yuhao Li, Qiaomei Lv, Wei Wang, Wenbo Ding, Yuanyuan Li · 2024 · BMC Cancer
  39. Development of Radiomics-Based Risk Prediction Models for Stages of Hashimoto’s Thyroiditis Using Ultrasound, Clinical, and Laboratory Factors
    Jiahui Chen, Kai Kang, Xinyue Wang, Jianning Chi, Xuemeng Gao, Yongxin Li, Ying Huang · 2025 · Ultrasound in Medicine & Biology
  40. Pembrolizumab-associated acral necrosis and esophageal necrosis
    Austin R. Thomas, Athira Jayan, Yusuf Chang, Reese A. Svetgoff, Saumil S. Datar, Vinayak Memula, Michael Huang, Laura Winikka, Jeffrey W. Chen · 2022 · Current Problems in Cancer Case Reports
  41. Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
    Mona A. Marie, Justin McCallen, Zahra Hamedi, Abdul Rafeh Naqash, Alexander Hoffman, Druid C. Atwell, Suneetha Amara, Mahvish Muzaffar, Paul R. Walker, Li V. Yang · 2022 · Frontiers in Oncology
  42. Correlation between serum thyroid stimulating hormone level and glycolipid metabolism in patients with polycystic ovary syndrome
    Zhongyue Chen, S. Jing, Yanyan Sun · 2023 · Medicine
  43. Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet
    Xizhao Sui, Duoji Danzeng, Ping Ni, Jiayi Geng, Pingcuo Gesang, Zhaxi Renqing, Yuling Wei · 2024 · Asian Journal of Surgery
  44. Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
    Jee Hee Yoon, Min‐Ho Shin, Hee Nam Kim, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho‐Cheol Kang · 2021 · Endocrinology and Metabolism
  45. Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Graves’ disease resulting in remission
    Ken Okamura, Kaori Sato, Megumi Fujikawa, Sachiko Bandai, Hiroshi Ikenoue, Takanari Kitazono · 2022 · Endocrine Journal
  46. Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
    Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami, Aya Fukuma Ozaki · 2025 · Cardio-Oncology
  47. Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
    Min Xiao, Lan Qian, Qiu Zhao, Jian Ma, Qianxiao Li, Qian Liu, Zhiyan Bi · 2025 · Oncology Letters
  48. Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy
    Nicole Huang, Jessica Ortega, Kyleigh Kimbrell, Joah Lee, Lauren N Scott, Esther Peluso, Sarah Wang, Ellie Y. Kao, Kristy Kim, Jarod Olay et al. · 2025 · JCI Insight
  49. Sex differences in thyroid dysfunction onset timing induced by immune checkpoint inhibitors: JADER disproportionality analysis
    Naohito Ide, Yuki Tsuruta, Ken-ichi Sako, Tomoji Maeda · 2026 · Expert Opinion on Drug Safety
  50. Atezolizumab-Induced Hypothyroidism in a Patient With Pre-existing Triiodothyronine (T3) Thyrotoxicosis Due to Graves’ Disease: A Case Report and Literature Review
    Samson Oghenetsovwe Oyibo, Mohamed O Mahgoub · 2021 · Cureus
  51. Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in Cancer
    Michelle Ferreira, Meghana Rao, Arif H. Kamal, Afreen Idris Shariff · 2022 · Journal of Palliative Medicine
  52. Endocrine adverse events in patients with malignant neoplasms receiving treatment with immune checkpoint inhibitors
    Kristina Zherebchikova, Yulia P. Sych, M. Amosova, Marina I Sekacheva, Valentin V. Fadeev, A. A. Vilenskiy · 2022 · Russian Medical Inquiry
  53. Transient Thyroiditis Followed by Exacerbation of Hypothyroidism After Immune Checkpoint Inhibitor Therapy (Nivolumab and Ipilimumab) in a Patient With Pre-existing Autoimmune Hypothyroidism: A Case Report
    Guy Hayakawa, Maya M. Leibowitz, Sudipta Datta, Samson Oghenetsovwe Oyibo · 2023 · Cureus
  54. Management and nursing strategies for different patterns of adverse events in patients with urological cancer treated with immune checkpoint inhibitors
    Xiaojuan Huang, Xiaolei Li, Lulin Ma, Chunxia Liu · 2023 · Current Urology
  55. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
    Stine K. Christensen, Mette Lerche Winther, Ida J. Laursen, Freja Sønder Madsen, Carsten Brink, Thomas Heiberg Brix, Eva Ellebæk, Inge Marie Svane, Frederikke S. Hansen, Charlotte Aaquist Haslund et al. · 2024 · Supportive Care in Cancer
  56. Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review
    Kaoruko Fukushima, Saori Kitayama, Manami Sazuka, Remi Kodera, Kazuhito Oba, Kenji Toyoshima, Yuko Chiba, Hiroshi Yamamoto, Atsushi Araki, Yoshiaki Tamura · 2024 · Cureus
  57. Reversible elevation of creatine kinase and creatinine caused by sintilimab-induced hypothyroidism: A case report
    Shurong Liu, Zhen-Guang Zhao, Rui-Ren Zhai, Li-Juan Wang, Chen Yang, Quan-Bin Ma, Li Wang · 2024 · Medicine
  58. Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study
    Ya Gao, Chunxia Du, Yan Xu, Xinqi Cheng, Haitao Zhao, Fang Jiang, Ninghai Cheng, Yang Xiang, Yuelun Zhang, Yuanmeng Li et al. · 2025 · The Journal of Clinical Endocrinology & Metabolism
  59. Thyroid Storm and Type 1 Diabetes Mellitus Induced by Combined Ipilimumab and Nivolumab Immunotherapy: A Case Report
    Vivek Ramburuth, Jeyanthy Rajkanna · 2023 · Cureus
  60. Case report: A rare case of immunotherapy induced isolated left CN VI palsy in a patient with unresectable melanoma
    Samantha Su Ping Low, Karim Hussien El-Shakankery, Ewan R. Brown, Alan Christie, Sally McCormack, Mark D. Stares · 2024 · Frontiers in Oncology
  61. Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18F-FDG PET/CT in Renal Cell Carcinoma
    Moulish Reddy, Mudalsha Ravina, Harish Goyal, Amit Kumar, Rutuja Kote · 2024 · Clinical Nuclear Medicine
  62. Thyroiditis While Receiving Programmed Death Ligand 1 (PD-L1) Inhibitor Therapy for Nonthyroid Cancers Is Associated with Improved Overall Survival
    Trevor E. Angell · 2020 · Clinical Thyroidology
  63. Immune checkpoint inhibitor–induced thyroiditis is a risk factor for acute and chronic kidney dysfunction
    Ian A. Strohbehn, Sarah Street, Donald F. Chute, Harish Shanthanu Seethapathy, Meghan D. Lee, Rituvanthikaa Seethapathy, Zsófia D. Drobni, Osama E. Rahma, Tomas G. Neilan, Leyre Zubiri et al. · 2021 · Nephrology Dialysis Transplantation
  64. Spontaneous recovery of immune checkpoint inhibitor‐induced thyroiditis with high free T4 level: A case report
    Rie Hagiwara, Daisuke Suzuki, Shiori Tonezawa, Rika Saikawa, Shunsuke Funazaki, Masashi Yoshida, Satoshi Washino, Tomoaki Miyagawa, Kazuo Hara, Hodaka Yamada · 2021 · Clinical Case Reports
  65. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
    Han-Sang Baek, Chaiho Jeong, Kabsoo Shin, Jaejun Lee, Dong‐Jun Lim, Moo Il Kang, Jeonghoon Ha · 2021 · Research Square
  66. Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
    Xiaolin Zhao, Xiaoyu Wang, Surui Liu, Pian Cheng, Jinjuan Chen, Jie Liu · 2025 · Frontiers in Immunology
  67. Early Prediction of Pembrolizumab-Induced Hypothyroidism Based on the Neutrophil-to-Lymphocyte Ratio
    Yusuke Nakazawa, Ako Gannichida, Hirofumi Utsumi, Jun Araya, Takashi Kawakubo · 2025 · Cureus
  68. Immunotherapy and Targeted Therapy Considerations in Head and Neck Oncology.
    R. Dagher, Alexander M. Khalaf, R. Ferrarotto, K. Learned · 2025 · The Radiologic clinics of North America
  69. Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab
    I-Wen Chen, Cheng-Wei Lin, Po‐Ting Lin, Wei Teng, Chung‐Wei Su, Tsung‐Han Wu, Yi‐Chung Hsieh, Wei-Ting Chen, Chen-Chun Lin, Shi-Ming Lin et al. · 2026 · Cancer Immunology Immunotherapy
  70. Combined immune checkpoint inhibitor–induced type 1 diabetes: a rare but serious endocrinopathy
    Kasra Emami, Sonia Goyal, VISHAL AKULA, Peggy Nana Ama Amoakohene · 2026 · JCEM Case Reports
  71. Thyroiditis Induced by Immune Checkpoint Inhibitors Exhibits High [68Ga]Ga-FAPI-46 and [18F]FDG Uptake on PET/CT
    Anne Hauge Thostrup, Morten Bentestuen, Thor L. Rasmussen, Weronika Maria Szejniuk, Helle Damgaard Zacho · 2026 · Clinical Nuclear Medicine
  72. Thyroid function and ultrasound surveillance in childhood cancer survivors (CCS): a position paper of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED)
    Gerdi Tuli, Valeria Calcaterra, Raffaella Di Mase, Maria Cristina Vigone, Roberto Gastaldi, Rosario Ferrigno, Nicola Improda, Antonella Klain, Maria Rosaria Licenziati, Valeria Pellino et al. · 2026 · Journal of Endocrinological Investigation
  73. Thyroid storm triggered by immune checkpoint inhibitor therapy
    Junya Hagiwara, Miku Sekine, Eiji Sakawaki, Sonoko Sakawaki, Yoshihiro Takeyama · 2026 · BMJ Case Reports
  74. Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report
    Jessica K. Williams, Anne K. Brinkman, Amori Y. Salami-Henry, Nupur J. Kikani, Steven P. Weitzman · 2026 · Clinical Medicine Insights Endocrinology and Diabetes
  75. Die Rolle der Wärmeregulation des menschlichen Organismus bei einer Krebserkrankung und die rote Muskulatur als mögliche Wärmequelle eines antitumoralen Fiebers
    Henning M. Schramm · 2019 · Der Merkurstab
  76. Alteraciones tiroideas asociadas con los inhibidores de los puntos de control inmunitario
    Enzamaría Fidilio, Elena Navarro-González, Ana R. Romero-Lluch, Pedro Iglesias, Juan José Díez Gómez, Emma Anda, Estefanía Santos Mazo, Carles Zafón · 2020 · Endocrinología Diabetes y Nutrición
  77. Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer
    Hannah Elizabeth Green, Jorge J. Nieva · 2021 · Journal of Investigative Medicine
  78. Nivolumab Safety in Renal Cell Carcinoma: A Case Report
    James Mark Debono, Dustin Balzan, John-Joseph Borg, Stephen Falzon, Dania Al-Haddad, Benjamin Micallef, Janet Sultana · 2023 · Journal of Pharmacy Technology
  79. Cemiplimab‐Induced Colitis Causing Hypovolemic Shock: A Case Report and Literature Review
    Saeed S. Graham, Kena J. Lemu, Victoria Mofopefoluwa Thomas, Stanley O Oghoghorie, Abdulazeez R. Swaiti, Jinye Liu, Alina Faheem · 2025 · JGH Open
  80. Endocrine
    Jeena Mary Varghese, Conor J. Best · 2022 · Springer eBooks
  81. Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8 + T cells Driven by IL21 Contribute to Checkpoint Inhibitor Thyroiditis
    Melissa G. Lechner, Zikang Zhou, Aline T. Hoang, Nicole Huang, Jessica Ortega, Lauren N Scott, Ho-Chung Chen, Anushi Y. Patel, Rana Yakhshi Tafti, Kristy Kim et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  82. Polyfunctional IL-21 + IFNγ + T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy
    Nicole Huang, Jessica Ortega, Kyleigh Kimbrell, Joah Lee, Lauren N Scott, Esther Peluso, Sarah Wang, Ellie Kao, Kristy Kim, Jarod Olay et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  83. Análise de disfunções tireoidianas induzidas pelo tratamento oncológico imunoterápico
    Karoline Laurentino Lopes Pinto, Ronan Wilk Guimarães, Gabriela Resende Vieira de Sousa · 2019 · Programa de Iniciação Científica - PIC/UniCEUB - Relatórios de Pesquisa
  84. Cancer Immunotherapy Related Endocrine Adverse Effects
    Hana Kim, Sun Wook Cho, Young Joo Park · 2019 · International Journal of Thyroidology
  85. History of Radiation to the Neck Increases the Risk of Denovo Thyroid Dysfunction after Receiving Immune Checkpoint Inhibitors
    Koosha Paydary, Muhammad Zain Farooq, Ankit Mangla · 2020 · Endocrines
  86. Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management
    Carolina Lopes, S Morgado, Ana I. Plácido, Fátima Roque, Manuel Morgado · 2021 · SN Comprehensive Clinical Medicine
  87. Endokrynologiczne powikłania nowych terapii przeciwnowotworowych
    Michał Miner, Michał Elbaum, Aleksandra Jawiarczyk-Przybyłowska, Eliza Kubicka · 2021 · Postępy Higieny i Medycyny Doświadczalnej
  88. The influence of monoclonal antibodies for cancer treatment on the endocrine system
    Kamil Dyrka, Daria Witasik, Agata Czarnywojtek, Katarzyna Łącka · 2021 · Postępy Higieny i Medycyny Doświadczalnej
  89. Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy
    Melissa G. Lechner, Anushi Y. Patel, Willy Hugo, Trevor E. Angell, Ho-Chung Chen, Marissa S. Pioso, Aline T. Hoang, Natalie Yakobian, Ethan C. McCarthy, Eduardo Rodrı́guez et al. · 2021 · Research Square
  90. Hyperthyreose: Ursachen, Diagnostik, Behandlung
    Martin Grußendorf · 2021 · MMW - Fortschritte der Medizin
  91. Endocrinology aspects of other clinical or physiological situations
    Antonia M. Brooke, Kagabo Hirwa, Claire Emily Higham, A A Lewis · 2021 · Oxford University Press eBooks
  92. Diagnosis and Management of Thyroiditis: Hashimoto, de Quervain, Riedel
    Marika D. Russell, Janet M. Chiang · 2021 · Springer eBooks
  93. Pharmacology of the Thyroid
    Samantha Kass Newman, Terry F. Davies · 2022 · Elsevier eBooks
  94. Inibitori dei checkpoint immunitari e patologia tiroidea
    Luca Patti, Laura Musso, Diego Ferone, Manuela Albertelli · 2022 · L Endocrinologo
  95. Thyroid Hormone Requirement in ICI-Associated Hypothyroidism Is Higher than in Hashimoto's Hypothyroidism
    Anupam Kotwal, Whitney Sears Goldner · 2022 · Clinical Thyroidology
  96. Immune checkpoint inhibitors
    2018 · Reactions Weekly
  97. Immune Checkpoint Inhibitor–Associated Thyroiditis Risk Lurking in the Ultrasound
    Samantha Sovich, Melissa G. Lechner · 2022 · Clinical Thyroidology
  98. Analysis of treatment results and survival rates with assessment of prognostic factors in locally advanced well-differentiated thyroid cancer
    Замира Ахмедовна Раджабова, M. A. Kotov, A. S. Mitrofanov, M. A. Radzhabova · 2022 · Medical alphabet
  99. Endocrine Complications and Paraneoplastic Syndromes
    Sai‐Ching J. Yeung, Robert F. Gagel · 2022 · Holland‐Frei Cancer Medicine
  100. Thyroid Gland
    2022 · American Registry of PathologyArlington, Virginia eBooks